Key Highlights
- Serina Therapeutics stock climbed 39.45% after-hours to reach $1.78, compared to its regular session close of $1.28.
- A $15 million private placement is scheduled to close on March 20, followed by a potential second $15 million tranche before April 30.
- Additional warrant exercises could generate up to $33.3 million, potentially funding operations through late 2027.
- Shares are priced at $2.25 in the offering — representing a 68% premium over the March 17 close.
- Greg Bailey, a board member with a history supporting Pfizer’s $11.6B Biohaven and $14B Medivation acquisitions, has been named Co-Chairman.
Serina Therapeutics (SER) experienced a dramatic after-hours rally Wednesday evening, climbing close to 40% following the biotech firm’s disclosure of a private placement that could generate as much as $63.3 million in combined proceeds.
Serina Therapeutics, Inc., SER
The significant price movement occurred after market close, when the company unveiled plans for an initial $15 million tranche set to finalize on March 20, 2026. An additional tranche worth up to $15 million could close by April 30.
Shares rose from their regular trading close of $1.28 — which reflected a 4.48% decline during standard hours — to $1.78 in extended trading.
The financing is structured at $2.25 per unit, marking a substantial 68% premium relative to the closing price on March 17. Each unit or pre-funded warrant includes half of a warrant granting the right to purchase shares at $5.00. With a four-year exercise window, full warrant utilization could inject another $33.3 million into company coffers, bringing total potential capital to $63.3 million.
For a clinical-stage biotechnology company, this capital infusion is significant. According to Serina, the funding should support operations well into the latter half of 2027.
Seasoned Investor Takes Leadership Role
The financing round is being spearheaded by Greg Bailey, M.D., an existing board member who will now assume the role of Co-Chairman alongside current chair Simba Gill, Ph.D.
Bailey brings considerable industry credibility. He previously backed Biohaven Ltd., which Pfizer acquired in 2022 for roughly $11.6 billion, as well as Medivation, purchased by Pfizer in 2016 for $14 billion.
This background resonated with market participants. When a figure with Bailey’s investment pedigree leads a capital raise — particularly in the volatile biotech sector — it often signals confidence and can influence investor sentiment.
Capital Deployment Strategy
The capital raised will primarily support Serina’s registrational study for SER-252, currently in Phase 1b and focused on advanced Parkinson’s disease. Patient enrollment is underway at clinical sites across Australia and the United States.
SER-252 is being pursued under the FDA’s 505(b)(2) approval pathway, which CEO Steve Ledger characterized as “capital-efficient.” Dosing of the first participant has already occurred.
Serina anticipates that safety data from Cohort 1 will enable progression to Cohort 2 during the third quarter of 2026. Top-line results from the single-ascending dose portion of the trial are projected for the first half of 2027.
The therapeutic candidate addresses a patient population of roughly 250,000 individuals with advanced Parkinson’s disease in the United States and Europe whose conditions remain insufficiently managed with existing therapies.
Despite Wednesday’s after-hours surge, the stock’s broader performance remains challenging. Over the past year, SER has tumbled 71.11%, trading within a 52-week range of $1.22 to $7.92. The company’s market capitalization currently stands at just $13.65 million, while its Relative Strength Index registers at 29.86 — indicating severely oversold conditions.
SER finished regular Wednesday trading at $1.28, down 4.48% for the session.
